Home > Inhibitors & Agonists > Metabolic Enzyme/Protease > Acetyl-CoA Carboxylase (ACC)
Cat. No. Product name CAS No.
DC10173 Firsocostat(ND-630,GS-0976) Featured

ND-630 is an acetyl-CoA carboxylase (ACC) inhibitor; inhibits human ACC1 and ACC2 with IC50 values of 2.1 and 6.1 nM, respectively.

DC10050 PF05175157 Featured

PF-05175157 is a potent and selective inhibitor of both acetyl-CoA carboxylase isoform ACC1 located primarily in liver and adipose tissue and isoform ACC2 dominant in skeletal and heart muscle, with IC50 values of 27 nM and 33 nM, respectively.

DC10381 TOFA

TOFA (RMI14514;MDL14514) is an allosteric inhibitor of acetyl-CoA carboxylase-α (ACCA ).

DC41253 Fluazifop-P-butyl

Fluazifop-P-butyl, a graminicide from arylophenoxypropionate group, is a acetyl-CoA carboxylase (ACCase) inhibitor.

DC44535 PF-05221304(Clesacostat) Featured

PF-05221304 is an orally bioavailable, liver-directed and dual ACC1 (and ACC2) inhibitor with IC50s of 7.5 nM for rat ACC1, 8.2 nM for rat ACC2, 12.4 nM for human ACC1 and 8.7 nM for human ACC2. PF-05221304 is a substrate for organic anion transport polyp

DC45904 CP-610431

CP-610431 is a reversible, ATP-uncompetitive, isozyme-nonselective acetyl-CoA carboxylase (ACC) inhibitor. CP-610431 inhibits ACC1 and ACC2 with IC50s of ~50 nM. CP-610431 can be used for the research of metabolic syndrome.

DC70163 A-908292

A-908292 is a highly potent and selective acetyl-CoA carboxylase 2 (ACC2) inhibitor with IC50 of 38 nM (hACC2), no activity against ACC1 (IC50>30 uM).

DC70172 ACC2 inhibitor 2e

ACC2 inhibitor 2e is a highly potent and selective acetyl-CoA carboxylase 2 (ACC2) inhibitor with IC50 of 1.9 nM and 1950 nM for ACC2 and ACC1, respectively.ACC2 inhibitor 2e exhibited good PK profile and in vivo antidiabetic efficacy in C57BL/6 mice.

DC70506 IMA-1

IMA-1 is a small molecule that interrupt the arachidonate 12-lipoxygenase (ALOX12)-acetyl-CoA carboxylase 1 (ACC1) interaction.IMA-1 markedly blocked diet-induced NASH progression in both male mice and Cynomolgus macaque therapeutic models.The anti-NASH efficacy of IMA-1 was comparable to ACC inhibitor in both species.IMA-1 directly binds to a pocket in ALOX12 proximal to its ACC1-interacting surface instead of inhibiting ALOX12 lipoxygenase activity.IMA-1 treatment did not elicit hyperlipidemia, a known side effect of direct inhibition of ACC enzymatic activity, in both mice and macaques.

Page 1 / Total 1 FirstPrevNextLastGoto